Future research
DISEASE, COMPLICATIONS
AYUSH 64 ought to be further evaluated for the treatment of mild and moderate COVID-19, both as mono and a combination therapy (modern medicine), in a phase III drug trial. Studies should also evaluate the potential of AYUSH 64 to block progression of COVID-19 to severe disease and reduce post-COVID-19 complications. Experimental evidence is required to validate its anti-viral and other health benefits.